NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Sound Pharmaceuticals, Inc.

Sound Pharmaceuticals, Inc.

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://soundpharma.com/

Last Round

Grant

May 11, 2022

Total Funding Raised

$27.6M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Sound Pharmaceuticals, Inc. is a biotechnology company that develops novel therapeutics for the treatment of hearing loss and neurological disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyhearing loss therapeuticstinnitus treatmentclinical-stage biotechebselensensorineural hearing lossdrug developmentotologyclinical trialssmall molecule drughearing restorationnoise-induced hearing lossbiopharmainner ear therapydrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Sound Pharmaceuticals, Inc. Comparables

Compare Sound Pharmaceuticals, Inc. with similar companies based on industry and business-model similarity.

Sound Pharmaceuticals, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Otologic Pharmaceutics
87%
Gateway Biotechnology, Inc.
87%
Audion Therapeutics
84%

Sound Pharmaceuticals, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 11, 2022
GrantApr 6, 2021
Series BJun 6, 2018
GrantSep 29, 2017
Series ASep 16, 2016
Grant
Jul 21, 2015

Key People

Founding team and executive leadership

Jonathan Kil

CEO, Chief Medical Officer

Executive Team

John Sullivan

Chief Financial Officer

Executive Team

Sound Pharmaceuticals, Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 7, 2026

    Grew 16% QoQ, from 19 to 22 employees.

  • Apr 24, 2026

    Grew 17% QoQ, from 18 to 21 employees.

Sound Pharmaceuticals, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Sound Pharmaceuticals, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Sound Pharmaceuticals, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range24
Year Founded2001
Last FundingMay 11, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.